Rapid resolution of hemorrhagic fever (Ebola) in Sierra Leone with ozone therapy

Abstract

Background: Ebola Virus Disease (EVD) has ravaged three countries in West Africa. The mortality rate is extremely high, and it is perceived not only as threat to all of Africa but to the entire world. There is no known treatment to date other than administration of convalescent blood or experimental monoclonal antibodies, which both often fail. Ozone therapy (OT) has been in clinical use for decades and has been found to have physiological effects, which should directly inactivate the virus itself, as well as modulate its damaging effects. We present the scientific background and the possibility of ozone therapy as a cure or prevention for EVD in five consecutive patients. Materials and Methods: Ozone therapy administration by a combination of direct intravenous gas administration, rectal gas administration and ozonized water was administered to three patients with known acute EVD, one with apparent acute infection, and one case of extremely high risk. Treatment was carried out for up to ten days despite fast total remission of symptoms. Vitamin C and glutathione supporting supplements were administered. Results: Four symptomatic patients, three with test positive EVD confirmation and one (who suffered Ebola contaminated needle stick contamination three days earlier) without lab confirmation all remitted symptoms within 2-4 days and fully recovered. All four ill cases had an immediate recovery course upon initiation of therapy. The single case of non-symptomatic high-risk exposure treated preventively did not develop symptoms. Conclusion:Ebola virus may have a very narrow window of redox infectivity capacity, which can be easily exploited with OT. OT may be a useful modality in EVD and other viral diseases and should be immediately studied to save lives that might otherwise be lost.

Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2

“…Rectal ozone therapy led to the complete remission of symptoms after 7 days in 5 symptomatic patients infected with Ebola, the hemorrhagic fever virus with high lethality (65%; Rowen et al, 2016 ). It has also been observed that O 2 -O 3 therapy is able to kill SARS-CoV-1 virus in monkey cells in vitro and to benefit patients with bronchopneumonia and neurological complications ( Li et al, 2020a ; Ricevuti et al, 2020 ).…”

Untitled

“…All survived without any deterioration of symptoms after ozone therapy began, nor did they have any post Ebola complications. The epidemic claimed 60% of its victims and scarred survivors with a 70+% rate of complications [31]. The key method was directly administering oxygen/ozone gas intravenously (DIV), 20 cc at 30-55 mcg of ozone/cc of gas over a few minutes.…”

Implicações sobre o uso do ozônio (O3) no tratamento coadjuvante do COVID-19

“…Com relação aos mecanismos antivirais do ozônio, acredita-se que o gás cause oxidação das glicoproteínas da superfície viral ocasionando a ruptura do invólucro viral, interrompe o contato vírus com os receptores das células alvo e perturba o ciclo de reprodução, uma vez que inativa a enzima transcriptase reversa, sendo que todos eventos relatados ocorrem sem ocasionar citotoxicidade aparente (Carpendale & Freeberg, 1991;Wells et al, 1991). Ainda, é relatado estímulo no sistema imunológico com a administração da ozonioterapia (Rowen et al, 2016).…”

“…Em 1991, Welles et al, em um estudo in vitro evidenciaram a inativação do vírus do HIV-1 utilizando soro tratado com ozônio (Wells, Latino, Gavalchin e Poiesz, 1991). Estudos mais recentes comprovam que o ozônio inativou tanto os vírus envelopados (cepa McIntyre do vírus do herpes simplex tipo 1 [HSV-1], vacinação cepa Elstree [VAC], vírus da estomatite vesicular cepa Indiana [VSV], cepa da gripe A [H1N1] A/WS/33) e vírus não envelopados (adenovírus humano tipo 2 [Ad2])(Valdenassi et al, 2020) Rowen et al (2016). administraram combinações de água ozonizada, ozônio intravenoso e retal em cinco pacientes com a doença do vírus Ebola por um período de 10 dias ou até a remissão do sintoma.…”